Metastatic Cancer Clinical Trial
— EXERTOfficial title:
Exercise Therapy in Radiation Therapy (EXERT)
Verified date | May 2023 |
Source | Milton S. Hershey Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate exercise therapy as a method for potentially improving radiation therapy treatment toxicities for metastatic cancer patients receiving radiation therapy.
Status | Completed |
Enrollment | 16 |
Est. completion date | January 31, 2023 |
Est. primary completion date | January 26, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males and females =18 years of age - Fluent in written and spoken English - Must be able to provide and understand informed consent - Must have an ECOG PS of = 2 - Diagnosed with metastatic disease - Cancer patients (stage 1-4) - Treatment to primary site or metastatic disease - Scheduled to receive radiation therapy at Penn State Cancer Institute - Absence of absolute contraindications for exercise according to the American Heart Association (see below) - Primary attending oncologist approval - Receiving treatment as an outpatient Exclusion Criteria: - Receiving radiation therapy at a location other than Penn State Cancer Institute - Not fluent in written and spoken English - Evidence in the medical record of an absolute contraindication for exercise - Performing > 90 minutes/week of physical activity at the time of initial evaluation - Cardiac exclusion criteria: - Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system - History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty or stenting within the past 6 months prior to the start of radiation therapy - Uncontrolled arrhythmias; patients with rate controlled atrial fibrillation for >1 month prior to start of radiation therapy may be eligible - syncope - acute myocarditis, pericarditis, or endocarditis - acute pulmonary embolus or pulmonary infarction - thrombosis of lower extremities - suspected dissecting aneurysm - pulmonary edema - respiratory failure - acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise - mental impairment leading to inability to cooperate - Pregnant women - In-patient receiving radiation therapy for a radiation emergency (e.g. cord compression, SVC syndrome, brain metastases) - High risk of fracture or spine instability (Mirels score =7, SINS =7) - Children (the protocol will only include individuals 18 and older) |
Country | Name | City | State |
---|---|---|---|
United States | Penn State Cancer Institute | Hershey | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Milton S. Hershey Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acceptability of exercise intervention: (number of patients agreeing to perform RT+ET)/(number approached) | (number of patients agreeing to perform RT+ET)/(number approached) | 1 year | |
Primary | Feasibility of exercise intervention: (number of patients who completed RT+ET)/(number agreeing to perform RT+ET) | (number of patients who completed RT+ET)/(number agreeing to perform RT+ET) | 1 year | |
Primary | Incidence of Treatment- Emergent Adverse Events | Safety of exercise intervention: freedom from any Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher event | 1 year | |
Secondary | Change in timed up and go | Timed up and go | 3 Months | |
Secondary | change in grip strength | Grip strength | 3 Months | |
Secondary | change in quality of life measured via the Godin Physical Activity Questionnaire | The Godin Physical Activity Questionnaire asks how much physical activity the participant engages in during a typical 7-day period. | 3 Months | |
Secondary | change in quality of life measured via the Barriers to Exercise RM 5-FM survey | The Barriers to Exercise RM 5-FM survey asks participants about barriers to being active. Response options include: very likely; somewhat likely; somewhat unlikely; very unlikely. | 3 Months | |
Secondary | change in quality of life measured via the Work Productivity and Activity Impairment Questionnaire | The Work Productivity and Activity Impairment Questionnaire ask about the effect of the participant's health problems on the ability to work and perform regular activities. A variety of question/response styles are included in the survey. | 3 Months | |
Secondary | change in quality of life measured via the Scored Patient-Generated Subjective Global Assessment | The Score Patient-Generated Subjective Global Assessment asks about participant nutrition. A variety of question/response styles are included in the survey. | 3 Months | |
Secondary | change in quality of life measured via the EORTC questionnaire | The EORTC Quality of life questionnaire asks a variety of questions about their health regarding physical abilities. Response options include: not at all; a little; quite a bit; very much. | 3 Months | |
Secondary | change in quality of life measured via the ECHO EXERT survey | The Experience of Care and Health Outcomes (ECHO) Survey asks three questions about participant experience with the exercise intervention. Response options include: not at all; not much; mixed; somewhat; very much so. | 3 Months | |
Secondary | change in quality of life measured via the Health Belief Scale | The Health Belief Scale asks questions regarding exercise therapy. Response options include: strongly disagree - strongly agree, where 1 equals strongly disagree and 4 equals strongly agree. | 3 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Withdrawn |
NCT00005030 -
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
|
Phase 1 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT04085029 -
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05981170 -
Rurality Adapted Physical Activity Sport Health
|
||
Not yet recruiting |
NCT03058809 -
Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood
|
Phase 1/Phase 2 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01302808 -
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT00918645 -
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
|
N/A | |
Completed |
NCT00795678 -
Chemotherapeutic Agents in Brain/Breast
|
N/A | |
Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
Completed |
NCT00557102 -
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
|
Phase 2 | |
Recruiting |
NCT00398437 -
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
|
N/A |